Clinical Trial Search

Primary: Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24 — 0.203; 0.208; 0.403 relapses per year

Primary: Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV) — -1.22; -0.99 Percent change

Primary: Rating of Urges to Smoke 24 Hours and One Week After the Target Quit Date Assessed by Mood and Physical Symptoms Scale — 2.47; 2.88 units on a scale — p=0.14

Primary: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of…

Primary: Event Rate of "All Hypoglycemia" Defined as the Total Number of Episodes Divided by the Total Duration of the On-treatment Period in Years (Events Per Patient-year)…

Primary: Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures — 1; 1; 1; 1 particpants

Primary: Number of Participants With Positive or Negative Results in PET, MRI or PET/MRI for Prostate Cancer Compared to Histological Findings — 36; 26; 35; 1 participants…

Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study…

Primary: Change in HbA1c From Baseline to Week 24 — -1.57; -0.90 percentage of total hemoglobin — p=<.0001

Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Success — 70; 95; 3 participants

Primary: Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection. — 274; 310 Participants

Primary: Percentage of Participants With a Significant Skin Event (Day 5 Cumulative) — 2.4 Percentage of participants

Primary: Immune Response 3 Weeks After Seasonal Influenza Vaccination — 53.3; 83.7 percentage of participants

Primary: Number of Participants With Adverse Events (AEs) — 416; 259 Participants

Primary: Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score. — 7.31; 5.53 Score on a scale